Stockwinners Market Radar for July 24, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:33 EDT SPDR Gold Shares holdings fall to 822.25MT from 823.13MT - This is the second consecutive decline in holdings.

18:57 EDT ServiceNow CEO: Signed 40 customers of $1M or greater in Q2 - In an interview on CNBC's Mad Money, ServiceNow CEO John Donahoe said: We're focusing on U.S. Federal business with Microsoft (MSFT)... We have 20 different product partnerships with Microsoft... There is lots of shared opportunity with Microsoft... We feel very good about our annual guidance... We continue to be optimistic about our business.

18:52 EDT Fly Intel: After Hours Movers - UP AFTER EARNINGS: Netgear (NTGR) up 8.4%... Anika Therapeutics (ANIK) up 7.8%... Meritage Homes (MTH) up 7.6%... AXT (AXTI) up 5.5%... Digimarc Corp (DMRC) up 3.5%... LeMaitre Vascular (LMAT) up 3.3%... Costamare (CMRE) up 3.1%... Knowles (KN) up 2.3%... TechnipFMC( FTI) up 2.3%... Facebook (FB) up 1.1%. DOWN AFTER EARNINGS: Align Technology (ALGN) down 21.7%... Oceaneering (OII) down 17.2%... PTC (PTC) down 13.5%... Spirit Airlines (SAVE) down 13.2%... Tesla (TSLA) down 9.3%... Ford (F) down 6.2%... Xilinx (XLNX) down 5.9%... Citrix (CTXS) down 5.7%... SLM Corp (SLM) down 5.6%... PayPal (PYPL) down 4.3%... Las Vegas Sands (LVS) down 3.3%... ServiceNow (NOW) down 3.3%... Allegiant Travel (ALGT) down 2.2%... F5 Networks (FFIV) down 1.5%. ALSO LOWER: Cara Therapeutics (CARA) down 9.8% after equity offering... Bristol Myers (BMY) down 3.9% after Part 2 of the Phase 3 CheckMate -227 trial did not meet primary OS endpoint for Opdivo plus chemotherapy versus chemotherapy in patients with first-line non-squamous non-small cell lung cancer. Movers as of 18:30ET.

18:49 EDT Tesla CFO says 'next 12 months will be most exciting yet' - Says given the company's cash on hand and stabilization in Model 3, believes the company is in great shape.

18:43 EDT Tesla CEO says will be 'breakeven' this quarter and profitable next quarter - Expect to be cash-flow positive in future quarters.

18:42 EDT FDA approves Eli Lilly's Baqsimi nasal powder - The U.S. Food and Drug Administration approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered without an injection. Baqsimi, which is a powder administered into the nose, will come in a single-use dispenser that can be given to someone suffering from a severe hypoglycemic episode. Baqsimi increases blood sugar levels in the body by stimulating the liver to release stored glucose into the bloodstream. It has the opposite effect of insulin, which lowers blood sugar levels. The FDA granted the approval of Baqsimi to Eli Lilly and Company.

18:31 EDT Archrock raises quarterly dividend 10% to 14.5c from 13.2c per share - The dividend will be paid on August 14 to all stockholders of record on August 7.

17:57 EDT Ford says 2019, 2020 'robust' product launch years - Says 2019 and 2020 "robust" product launch years. Says results in quarter and YTD show that business is "meaningfully improving." Says has "many opportunities" to drive free cash flow. Says still committed to maintaining strong balance sheet.

17:43 EDT Packaging Corp. reports Q2 adjusted EBITDA $376.2M vs. $382.3M last year

17:36 EDT Ford seeing 'discrete' signs of stability in China - Says Q2 results demonstrate global redesign is leading to positive shifts in the company's business. Says company trajectory improving in terms of growth, cash flow, and profitability. Says seeing discrete signs of stability in China. Says delivered $2.1B in adjusted free cash flow YTD. Comments taken from Q2 earnings conference call.

17:30 EDT Facebook says sees sales growth slowing into 2020 - Says: Expects revenue growth to decelerate going forward, more so in Q4 and into 2020...Ad growth slowdown due to ad targeting-related headwinds... Lowering 2019 CapEx view to $16B-$18B.

17:24 EDT Washington Prime announces sale leaseback of $98.9M for fee interest - Washington Prime announced that it has signed a definitive agreement for the sale and leaseback of four assets. Under the agreement, an affiliate of Perennial Investments & Advisors, an institutional fee investor, will acquire a fee interest in the land at the properties for a price of approximately $98.9M. Concurrently, Washington Prime will enter into a new 99-year master ground lease for a leasehold interest in the land at the properties. The company will, however, continue to own a fee interest in the improvements through the term of the aforementioned master ground lease and continue to manage, lease and develop the properties, offering the same exceptional guest experience. It will be business as usual to guests and property employees with the company continuing to maintain full control over the leasehold interest in the land and fee interest in the improvements at the respective properties. The master ground lease includes fixed annual payments to the ground lessor and contains annual rent escalators over the term. The agreement includes an option for the company to repurchase the fee interest in the land at a fixed price in year 30 of the master ground lease. If the company does not exercise this option, then the fee interest in both the land and improvements will transfer to the ground lessor at the end of the 99-year ground lease term. The properties, which represent an aggregate 3.9M square feet of retail space, are: Edison Mall, located in Fort Myers, Florida; Great Lakes Mall, located in Mentor, Ohio; Irving Mall, located in Irving, Texas and Jefferson Valley Mall, located in Yorktown Heights, New York. The company expects to complete the sale leaseback transaction in the second half of 2019, subject to due diligence and customary closing conditions.

17:17 EDT Aurora Cannabis, UFC launch research on use of CBD products by MMA athletes - Aurora Cannabis and UFC announced the launch of a joint clinical research program that will produce multiple studies under the terms of their recently announced partnership. The research will examine the use of hemp-derived CBD as an effective treatment for pain, inflammation, wound-healing, and recovery on MMA athletes. Once research is complete, any resulting product will come to life in the U.S. under the new high-performance sports brand ROAR Sports, a portfolio of high-quality, hemp-derived CBD topical treatments scientifically formulated with elite athletes in mind. Through analysis of athlete needs and scientific data, ROAR Sports will challenge the status quo, seek to alleviate the stresses of competition, and earn designation as the "Official CBD product of UFC."

17:10 EDT Agnico Eagle still expects 2019 production 1.75M oz. og golf - Agnico Eagle's total production guidance remains unchanged at 1.75 million ounces of gold, including pre-commercial production from Meliadine and Amaruq. The company anticipates that total cash costs per ounce and AISC per ounce for 2019 will continue to be in the range of $620 to $670 and $875 and $925, respectively. Increased expected total capital costs at $750M from $660M.

17:08 EDT Rush Enterprises sees 'widespread activity in commercial vehicle market' - CEO WM Rush says: "A healthy economy, widespread activity in the commercial vehicle market and the continued execution of our aftermarket strategic initiatives positively impacted our results in the second quarter. Our truck sales outpaced the commercial vehicle market in both Class 8 and Class 4-7, and we achieved record performance in medium-duty truck sales this quarter."

17:07 EDT Spirit Airlines drops 13% after reporting operating expenses up 14.8% YoY - Spirit Airlines Q2 operating expenses increased 14.2% year over year to $849M. Adjusted operating expenses for the second quarter 2019 increased 14.8% year over year to $847.5M. These changes were primarily driven by higher flight volume, higher passenger re-accommodation expense, higher salaries, wages and benefits, and airport rent and landing fees. Aircraft fuel expense increased in the second quarter 2019 by 7.6 percent year over year, due to a 15.4 percent increase in fuel gallons consumed. Aircraft fuel expense increased in the second quarter 2019 by 7.6 percent year over year, due to a 15.4 percent increase in fuel gallons consumed. Spirit reported second quarter 2019 cost per available seat mile, excluding operating special items and fuel, of 5.41c, up 4.6% compared to the same period last year. As previously disclosed, a severe storm system impacted a large majority of Spirit's flights to and from Florida during the Easter holiday weekend. As a result, the Company canceled numerous flights and incurred costs of about $6 million for passenger re-accommodation and disrupted crew expense. Shares of Spirit Airlines are down about 13% in after-hours trading or $7.09 to $47.96 per share.

17:03 EDT Oceaneering sees 'moderately higher revenue' in Q3 - CEO Roderick A. Larson says: "For the third quarter of 2019, compared to the second quarter, we are expecting a slight improvement in our overall operating results on moderately higher revenue. For our energy segments, we expect declines in operating contribution from our ROV segment on flat activity levels due to a change in operating mix, a decline in profitability in Subsea Products, due to a greater proportion of segment revenue coming from manufacturing, and relatively flat results in our Subsea Projects and Asset Integrity segments. For our non-energy segment, Advanced Technologies, we expect revenue to increase and operating margins to improve to the low double-digit range."

17:02 EDT O'Reilly down 1.1% after reporting Q2 results, giving Q3, FY19 guidance

16:51 EDT Live Nation acquires OCESA Entretenimiento, terms not stated - Live Nation (LYV) has entered into definitive agreements to acquire a controlling interest in OCESA Entretenimiento, a promoter in Latin America and owner of Ticketmaster Mexico from CIE and Grupo Televisa (TV), the "largest multimedia company in the Spanish-speaking world." As part of the transaction, Live Nation will also acquire an interest in OcesaSeitrack, OCESA's booking and artist management joint venture; CREA, one of Mexico's special and corporate event specialists; and Centro Citibanamex, an exhibition and convention center in Mexico City. Soberon Kuri will serve as CEO and sit on the board of the newly-formed joint venture. Rapino will become Chairman of the venture's board of directors. The acquisition has been approved by the boards of directors of Live Nation, CIE, and Televisa. The consummation of the transactions is subject to the approval of the relevant regulatory authorities and other customary closing conditions. Live Nation anticipates that the transactions will close by the end of 2019.

16:39 EDT Enservco appoints Marjorie Hargrave CFO - Enservco Corporation announced the appointment of Marjorie Hargrave as CFO. Hargrave succeeds Dustin Bradford, who will remain with the company to assist in the transition prior to pursuing other interests. Hargrave is the former CFO of CTAP.

16:38 EDT Xilinx down 6% to $124.31 after Q2 revenue guidance misses estimates

16:37 EDT USD Partners raises quarterly distribution 0.7% to 36.5c per unit - USD Partners announced that the Board of Directors of its general partner declared a quarterly cash distribution of $0.3650 per unit for the second quarter of 2019, representing an increase of $0.0025 per unit or 0.7% over the prior quarter and 2.8% over the second quarter of 2018. The distribution is payable on August 14, 2019, to unitholders of record at the close of business on August 6, 2019.

16:35 EDT Pennsylvania American Water acquires Turbotville wastewater assets - Pennsylvania American Water, a subsidiary of American Water, announced that it has acquired the water assets of the Municipal Authority of the Borough of Turbotville and the wastewater assets from the Borough of Turbotville in Northumberland County. The purchase price for both systems combined was $1 million. The water system serves approximately 320 customers in Turbotville and a portion of Lewis Township, while the wastewater system serves approximately 290 customers in Turbotville. As part of the acquisition, Pennsylvania American Water plans to construct a new $3.2 million wastewater treatment plant, replacing the existing plant that was constructed in the 1980s. The new plant will be constructed near the existing plant with completion anticipated for 2022. The company also plans to replace water meters for all customers.

16:34 EDT O'Reilly Automotive sees Q3 comparable store sales up 3%-5%

16:33 EDT Northern Oil and Gas says Ground Game strategy continues success - Northern Oil and Gas announced a midyear update on its ground game acquisition strategy, which is Northern's regular acquisition activity excluding larger, separately announced deals such as the recent VEN Bakken acquisition. As part of this update, Northern is seeking to enhance its capital expenditures disclosure by providing both the acquisition capital spent to close Ground Game deals, as Northern has historically done, and also breaking out the incremental drilling and completion capital generated by Ground Game deals, to distinguish it from previously budgeted organic D&C capital. Northern is also providing a preliminary second quarter 2019 operations and balance sheet update. Volatility in oil prices in late 2018 and 2019 has led to a rich environment of Ground Game opportunities in the Williston Basin. Northern has committed to or closed on approximately 40 Ground Game acquisitions in the second quarter and third quarter-to-date of 2019, consisting of approximately 6,325 net acres, 0.2 net wells currently producing, and 6.1 net wells in process. In total, Northern expects these wells in process to produce approximately 2,000 Boe per day in 2020, with additional significant long-term development potential on the leasehold. As previously disclosed, growth in the Williston Basin has been constrained in the first half of 2019 due to infrastructure bottlenecks, primarily associated with gas gathering and processing infrastructure. Multiple midstream systems are scheduled to go in service in late 2019 and early 2020. These constraints reduced Northern's production levels relative to our assets' overall capability and led to higher per unit operating costs. Despite these issues, Northern expects its second quarter 2019 production to be near the middle of its guidance range, approximately 34,965 Boe per day, 80.5% oil, with LOE per unit costs modestly higher than the first quarter of 2019. Northern expects second quarter 2019 average unhedged realized oil prices of approximately $54.60 per barrel and natural gas prices of approximately $2.70 per Mcf, representing improved pricing differentials compared with the first quarter of 2019. Northern estimates that curtailments reduced its production by approximately 2,800 Boe per day in the first quarter of 2019 and 2,500 Boe per day in the second quarter of 2019. Northern now expects similar levels of curtailment to persist through the third quarter and likely well into the fourth quarter of 2019, longer than previously anticipated. However, Northern expects a robust completion schedule, Ground Game additions and the closing of the VEN Bakken acquisition to drive sequential growth in the second half of 2019 and into 2020. The ultimate timing and scale of Northern's production growth will be driven in part by the timing of major gas processing systems scheduled to come online in late 2019 and early 2020. Northern estimates that it added approximately 8.1 net wells to production in the second quarter and, aided by Ground Game activity, Northern's net wells in process continue to grow. Northern expects second quarter organic D&C capital expenditures of approximately $73.9 million, similar to first quarter levels, as expected.

16:32 EDT Regenxbio and Neurimmune to develop antibodies for neurodegenerative diseases - Regenxbio and Neurimmune, a clinical-stage Swiss biotech company translating human immune memory into antibody therapeutics, announced an exclusive license, development and commercialization agreement to discover and develop novel AAV gene therapies using NAV Vectors to deliver human antibodies against targets implicated in chronic neurodegenerative diseases, including tauopathies. Under the exclusive license, development and commercialization agreement, Regenxbio and Neurimmune will jointly develop and commercialize novel therapies using AAV vectors to deliver human antibodies. Initially, the companies will focus on diseases associated with the accumulation and deposition of the microtubule-associated protein tau - tauopathies. Regenxbio and Neurimmune will be jointly responsible for the design and development of vectorized antibody therapies and will share associated development costs equally. Following an initial research phase, on a target-by-target basis, each party will have the option to continue as a co-development and co-commercialization partner in the collaboration or to elect to receive a phase-based worldwide royalty in lieu of continued development investment.

16:30 EDT PayPal drops 6% to $113.98 after revenue outlook misses estimates

16:28 EDT Las Vegas Sands down 4.5% to $62.00 after Q2 results miss estimates

16:27 EDT Fluor says DoE extends Savannah River Site contract through Sep 2020 - Fluor Corporation announced that the U.S. Department of Energy has extended the Fluor-led Savannah River Nuclear Solutions, LLC management and operating contract at the Savannah River Site near Aiken, South Carolina. Fluor booked its share of the $1.8 billion contract extension, which is for an additional 14 months with two 12-month options, in the third quarter of 2019. SRNS was originally awarded the Savannah River management and operating contract in January 2008. SRNS will continue uninterrupted management and operation activities at the site as outlined in the contract.

16:26 EDT General American Investors authorizes additional 2M share repurchase - The General American Investors board of directors authorized the repurchase of an additional 2,000,000 outstanding shares of common stock when the shares are trading at a discount from the underlying net asset value by at least 8%. This continues a repurchase program which began in March 1995. Through June 30, 2019, the Company has repurchased 28.4 million shares of common stock for $842 million at an average discount of 13.7%.

16:25 EDT Regenxbio expands pipeline for HAE and neurodegenerative diseases - Regenxbio announced an expansion of its pipeline to include novel treatments for hereditary angioedema - HAE - and neurodegenerative diseases, including tauopathies, using NAV Vectors to deliver therapeutic antibodies. Regenxbio's new gene therapy product candidate for the treatment of HAE utilizes NAV Vectors that are designed to deliver a gene encoding a therapeutic antibody that targets and binds to plasma kallikrein, a key protein left unregulated in patients with HAE. In addition, Regenxbio and Neurimmune AG announced an exclusive license, development and commercialization agreement to discover and develop novel AAV gene therapies using NAV Vectors to deliver human antibodies against targets implicated in chronic neurodegenerative diseases, including tauopathies.

16:24 EDT Oneok raises quarterly dividend to 89c per share - The board of directors of ONEOK increased ONEOK's quarterly dividend 2.5c per share to 89c per share. This increase results in an annualized dividend of $3.56 per share. The dividend is payable Aug. 14 to shareholders of record at the close of business Aug. 6.

16:22 EDT HNI Corporation CEO says inconsistent demand impacted the quarter - CEO Jeff Lorenger states: "Our teams are performing well - managing through dynamic market conditions while staying focused on our key initiatives. Our efforts to drive operational efficiencies are on-track and bearing fruit. We are seeing strong momentum in our contract business. Our hearth business is executing well while navigating a slower housing market. We continue to see inconsistent demand in our supplies-driven business, which negatively impacted the quarter. We are confident in our ability to deliver profit improvement in the second half."

16:22 EDT Turning Point Brands invests in ReCreation Marketing - Turning Point Brands announced it has invested $3 million for a 30% stake in ReCreation Marketing, a Canadian distribution entity. ReCreation is a specialty marketing and distribution firm focused on building brands in the Canadian smoking, vaping and alternative products categories. ReCreation's management has significant expertise in marketing and distributing tobacco products throughout Canada, with over 50 years of combined experience building and managing a portfolio of premium brands. ReCreation's management is supported by a team of expert sales associates who serve up to 30,000 traditional retail outlets and newly-established cannabis dispensaries across Canada. ReCreation also supports RoseLife Science, a leading cannabis product innovator, producer, service provider and marketer located in Quebec.

16:20 EDT Brighthouse Financial names Ed Spehar new CFO - Brighthouse Financia announced that Edward Spehar will join Brighthouse Financial on July 29, 2019 and will assume the position of executive vice president and CFO, effective August 12, 2019. Spehar will succeed Conor Murphy, who was named interim chief financial officer in February 2019. Murphy will continue as the company's executive vice president and chief operating officer.

16:17 EDT Gemphire Therapeutics signs out-licensing partnership for gemcabene - Gemphire announced that the company has signed an out-licensing partnership with Beijing SL Pharmaceutical Co. to advance its drug candidate, gemcabene, into the Chinese market. This partnership is expected to provide an upfront gross payment of $2.5M to Gemphire and back end milestone and royalty payments to the combined company if certain development and commercialization milestones are met.

16:16 EDT Gemphire Therapeutics to merge with NeuroBo Pharmaceuticals - Gemphire Therapeutics (GEMP) and NeuroBo Pharmaceuticals, a privately-held clinical-stage biotechnology company, announced that they have entered into a definitive agreement whereby NeuroBo will merge with a wholly-owned subsidiary of Gemphire in an all-stock transaction. Upon completion of the merger, Gemphire will change its name to NeuroBo Pharmaceuticals, and plans to change its ticker symbol on the Nasdaq Capital Market to "NRBO." The merged company will focus on the development of NeuroBo's clinical-stage drug candidates for the treatment of neurodegenerative diseases.

16:14 EDT Facebook shares rally 3%, or $6.07, to $210.73 following Q2 results

16:13 EDT Facebook recorded additional $2B accrual in Q2 for FTC settlement - Facebook said in its earnings release, "In July 2019, we entered into a settlement and modified consent order to resolve the inquiry of the FTC into our platform and user data practices. Among other matters, our settlement with the FTC requires us to pay a penalty of $5.0 billion and to significantly enhance our practices and processes for privacy compliance and oversight. In particular, we have agreed to implement a comprehensive expansion of our privacy program, including substantial management and board of directors oversight, stringent operational requirements and reporting obligations, and a process to regularly certify our compliance with the privacy program to the FTC. In the second quarter of 2019, we recorded an additional $2.0 billion accrual in connection with our settlement with the FTC, which is included in accrued expenses and other current liabilities on our condensed consolidated balance sheet."

16:11 EDT Facebook says more than 2.1B people now use products every day - Facebook estimates that more than 2.1B people now use Facebook, Instagram, WhatsApp, or Messenger every day on average, and more than 2.7B people use at least one of its family of services each month.

16:10 EDT Facebook reports June DAUs up 8% to 1.59B, headcount up 31% to 39,651 - Facebook reports daily active users were 1.59B on average for June 2019, an increase of 8% year-over-year and monthly active users were 2.41B as of June 30, 2019, an increase of 8% year-over-year. The company's mobile advertising revenue represented approximately 94% of advertising revenue for Q2, up from approximately 91% of advertising revenue in Q2 of last year. The company's capital expenditures, including principal payments on finance leases, were $3.78B for Q2. Its cash and cash equivalents and marketable securities were $48.60B at the end of Q2. Its headcount was 39,651 as of June 30, 2019, an increase of 31% year-over-year.

16:08 EDT Facebook says FTC opened antitrust investigation in June against company - Facebook said in its earnings release, "The online technology industry and our company have received increased regulatory scrutiny in the past quarter. In June 2019, we were informed by the FTC that it had opened an antitrust investigation of our company. In addition, in July 2019, the Department of Justice announced that it will begin an antitrust review of market-leading online platforms."

16:07 EDT Netgear board authorizes incremental repurchase of up to 4.5M shares - The Netgear board authorized the repurchase of up to an incremental 4.5M shares of the company's common stock, or approximately 14.5% of outstanding shares.

16:06 EDT Facebook reports Q2 daily active users for June up 8% year-over-year to 1.59B

16:04 EDT Cyberoptics announces $3M share repurchase authorization - CyberOptics Corporation announced that its Board of Directors has authorized a $M share repurchase program through June 30, 2020. The common stock will be acquired from time to time in open market transactions, block purchases and other transactions complying with the Securities and Exchange Commission's Rule 10b-18.

16:02 EDT SEI Investments raises share repurchase authorization to $280M

16:02 EDT Regeneron granted FDA orphan status for treatment of retinopathy of prematurity - Regeneron was granted FDA orphan status for its treatment of retinopathy of prematurity, according to a post to the agency's website. Reference Link

16:01 EDT Gemphire Therapeutics trading halted, news dissemination

15:27 EDT Kumar says partnerships allow Anixa to spend less, have 'very low cash burn' - Anixa Biosciences (ANIX) is a biotech company focused on harnessing the body's immune system in the fight against cancer. In an exclusive interview with The Fly, the company's CEO Amit Kumar discussed Anixa's business model and ongoing partnerships: "I think there is an important distinction on how we work as opposed to a traditional biotech company. Most biotech companies are really, really capital-intensive. They have to spend a lot of money building lots of R&D labs, hiring a lot of people and performing the R&D. We decided that rather than 'reinvent the wheel,' there's lots of excess research and development capacity that exists and academic research that are some of the top academic research centers in the world... We decided than instead of building our own R&D labs, we would go work with the top academic research centers on the development of our products. This enables us to spend less money and, number two, it allows us to work with the world's experts in any particular field. For example, our CAR-T we're working with the Moffitt Cancer Center, which is one of the probably the top academic center developing CAR-T technology. For the vaccine, we're working with the Cleveland Clinic, the world's experts in this area. For the Ccheck, we're working with The Wistar Institute that has a professor who is the world's expert on the type of white blood cell we focus on. This allows us to work with the top-notch experts in any particular field, and we can do projects in all sorts of different fields this way because we're already accessing the experts in those fields. It gives us the ability to very quickly diversify our portfolio of products and technologies, and it allows us to do it all with a very, very low cash burn." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

15:12 EDT J.B. Hunt CFO sells 6,141 common shares - In a regulatory filing, J.B. Hunt CFO David G. Mee disclosed the sale of 6,141 common shares of the company at a price of $103.8161 per share.

14:52 EDT Azul, Avianca Holdings announce interline agreement - Azul (AZUL), the largest airline in Brazil by number of flight departures and cities served, and Avianca Holdings (AVH), one of the largest airline holding companies in Latin America headquartered in Colombia, announced an interline agreement, resulting in greater connectivity to customers of both airlines. The companies announced they "are now selling tickets jointly for flights between their route networks, allowing customers to travel with one ticket, check-in once, and to check bags through their final destination."

14:33 EDT Nucor CEO sells 19,193 common shares - In a regulatory filing, Nucor chairman, president, and CEO John J. Ferriola disclosed the sale of 19,193 common shraes of the company at a price of $56.37 per share.

14:26 EDT Kumar says Cleveland Clinic partnership big for Anixa, breast cancer patients - Anixa Biosciences (ANIX) is a biotech company focused on harnessing the body's immune system in the fight against cancer. In an exclusive interview with The Fly, the company's CEO Amit Kumar talked about its recently announced partnership with Cleveland Clinic for a potentially first-ever breast cancer vaccine: "This is a big partnership not only for the company but also for potential sufferers of breast cancer. Cleveland Clinic researchers have been working on a way to develop a vaccine against a number of different types of breast cancer, but specifically the most aggressive form called triple negative breast cancer - TNBC. TNBC is the type of cancer that results in the highest number of deaths from breast cancer. It's very aggressive and we don't have really good ways of treating it. Cleveland Clinic researchers have identified a way to try and vaccinate an individual, a woman, so that it doesn't even allow the breast cancer to happen. If you can imagine a world where instead of having to go through surgeries and chemotherapy and what not... We might be able to just give women a shot and never have to worry about breast cancer. That's a pretty big deal for society. From a commercial standpoint when you think about therapies for cancer, those therapies are only given to patients after they have cancer. For example, in the United States this year we're expecting about 268,000 breast cancer diagnosis, so the market opportunity for therapy against breast cancer is about 268,000. But a vaccine is given to women before they get the breast cancer. In the United States, there are about 50 million women who are above 40 and would be eligible for the vaccine. The market opportunity is very, very big for this type of therapy or vaccine as opposed to waiting until a woman has breast cancer." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

14:10 EDT Chicago Capital reports 5.2% passive stake in Stewardship Financial - In a regulatory filing, Chicago Capital disclosed a 5.2% stake in Stewardship Financial, which represents 452,725 shares. The filing does not allow for activism.

14:01 EDT Market opportunity for breast cancer vaccine 'very, very big,' says Anixa's CEO

14:00 EDT Partnerships allows Anixa to spend less, take advantage of expertise, CEO says

13:50 EDT Umpqua Holdings director Luis Machuca sells 10K shares of company stock - Umpqua Holdings director Luis Machuca disclosed in a filing that he had sold 10,000 shares of company stock at an average price of $16.77 per share on July 23. The total transaction value of the sale was $167,700.

12:51 EDT Southern Copper climbs after earnings meet expectations - Shares of Southern Copper (SCCO), a miner, explorer and refiner in Peru, Mexico, Argentina, Ecuador and Chile, are moving higher after the company reported earnings for its second fiscal quarter on Tuesday. The copper miner reported Q2 earnings per share of 52c on revenue of $1.8B, in-line with consensus estimates. Net income decreased to $402.4M the quarter from the $409.6M reported in the year-ago period. PROJECT LICENSE GRANTED: German Larrea, Chairman of the Board, commenting on the company's progress said that on July 8, the company received the construction license for the Tia Maria project. Larrea said, "We strongly believe this $1.4B project will further improve the company's asset base and profitability with an increase of 120,000 tons of annual copper production capacity at a very competitive cash cost." COPPER PRICES: According to Kitco Metals, Marcin Chludzinski, the CEO of Polish miner KGHM sees copper prices moving around $6,000 per tonne by the end of the year. "I do not see any reasons for a radical deterioration in price parameters. I think one should expect the copper price to oscillate around $6,000 per tonne by the end of the year," said the executive. PRICE ACTION: Shares of Southern Copper are up nearly 1% to $37.66. OTHERS TO WATCH: Other publicly traded stocks in the industry include BHP Group (BHP), Rio Tinto (RIO), Vale (VALE) and Freeport McMoRan (FCX).

12:21 EDT Northrop Grumman sees 'strong' results for remainder of year - Says realizing revenue synergies sooner than expected. Says Technology Services sales comparable to prior year period. Says no change to free cash flow guidance. Says intends to retire about $500M in debt in Q3. Sees growing cash flows as a result of growing earnings, working capital improvements, and pension plans beyond this year. Says Q2 a "strong" quarter. Sees "strong" results for the remainder of the year. Comments taken from Q2 earnings conference call.

12:01 EDT Rollins falls -10.8% - Rollins is down -10.8%, or -$4.12 to $34.03.

12:00 EDT Tupperware Brands falls -18.5% - Tupperware Brands is down -18.5%, or -$3.29 to $14.53.

12:00 EDT Constellium rises 10.7% - Constellium is up 10.7%, or $1.12 to $11.55.

11:56 EDT Caterpillar sees mining CapEx growth 'slow, steady' not 'volatile' - Management said the company is still very committed to profitably growing the business.

11:51 EDT LVMH CEO says 'entering second half of the year with confidence' - Bernard Arnault, Chairman and CEO of LVMH, said: "LVMH has made an excellent start to the year. These results once again illustrate the effectiveness of our strategy and the exceptional desirability of our Maisons, whose products transcend time. Their constant demand for quality and their consistently refreshed creativity are key to LVMH's success, always guided by a long-term vision, combining exemplarity and responsibility in all the company's actions. Despite buoyant demand, we will continue to manage costs and remain vigilant into the second half of the year. We are therefore entering the second half of the year with confidence and count on the talent of our teams and their shared entrepreneurial passion to further increase, once again in 2019, our leadership in the world of high-quality products."

11:44 EDT Caterpillar 'not dependant on new locomotives' in America

11:42 EDT Boeing: Temporary 737 MAX shutdown could be more efficient than low production - The company says that a temporary 737 MAX shutdown could be more efficient than a sustained low production rate, if needed.

11:37 EDT Caterpillar says nothing to indicate change in underlying demand

11:29 EDT Caterpillar says second half buybacks to be at same level as first half - Comments provided during Q2 earnings conference call.

11:19 EDT Boeing CEO says looking at 'every dimension' of 737 MAX program

11:03 EDT Merck announces plans to initiate Phase 3 trials of islatravir - Merck announced the results from a Phase 2b clinical trial evaluating the efficacy, tolerability, and safety of islatravir, the company's investigational nucleoside reverse transcriptase translocation inhibitor, for the treatment of HIV-1. The trial evaluated three oral, once-daily doses of islatravir initially for 24 weeks in combination with Merck's doravirine plus lamivudine, and then for a further 24 weeks in combination with doravirine, compared to DELSTRIGO in adults with HIV-1 infection who had not previously received antiretroviral treatment. At all dose levels, the combination of islatravir and doravirine maintained antiviral activity as measured by the number of study participants achieving HIV-1 RNA levels less than50 copies/mL, similar to DELSTRIGO at Week 48 of the study. These findings were presented as a late-breaking oral presentation at the 10th International AIDS Society Conference on HIV Science. Based on these data, Merck plans to initiate a Phase 3 program evaluating islatravir in combination with doravirine across diverse patient populations to address the evolving needs of people living with HIV-1.

11:00 EDT Boeing to study 'all levers' to minimize 737 MAX impact - Says any changes to 737 assumptions could force company to recognize additional financial impact. Says 737 MAX compensation costs to airlines expected to impact cash flow in 2019 and beyond.

10:51 EDT Pluristem CEO says reverse split 'important step' to improve capital structure - Pluristem Therapeutics issued an update to its shareholders from its CEO Yaky Yanay commenting on the company's proposed reverse stock split. The company said, "eW announced a 1-for-10 reverse split of the company's authorized, as well as issued and outstanding shares of common stock and authorized preferred stock. We elected to execute the reverse split at this time, as we believe that it is an important step to improve our capital structure and market positioning while also maintaining compliance with the Nasdaq minimum bid price requirement. We plan to continue adopting a proactive financial approach that will enable us to better control our capital structure, which we believe is essential to achieve our goals and long term growth plan. By executing this reverse stock split, I see a potential opportunity to attract high-quality healthcare investors who have shown interest in our technology and pipeline but are sometimes technically unable to invest in Pluristem's shares due to low market price. Strengthening our capital structure also places us in what I believe is a good position to advance business collaborations that can support the growth of our company as we move towards important milestones."

10:37 EDT Boeing CEO says may consider further 737 output costs or shutdown if warranted

10:35 EDT Boeing CEO says 737 MAX crashes 'continue to weigh heavily on us' - CEO Dennis Muilenburg says on Boeing's Q2 earnings conference call that the two 737 MAX crashes "continue to weigh heavily on us." Says currently working on software changes to address FAA requirement. Says Boeing will submit final certification package once all requirements have been satisfied, somewhere in the September timeframe. Says company "working tirelessly" to meet FAA requirements. Says board committee to review processes, designs for aircraft. Says conducts weekly technical calls with customers worldwide. Says could return 737 MAX to service early in Q4.

10:25 EDT Freeport McMoRan looks to add 200M lbs of copper in Americas

10:16 EDT Freeport McMoRan says 'significant' Grasberg output 'highly likely' beyond 2041

10:10 EDT Berkshire Hills Bancorp sees NIM remaining relatively stable

10:08 EDT Freeport McMoRan backs FY19 copper, gold sales guidance - Freeport McMoRan management said they are reaffirming FY19 sales guidance of 3.3B pounds of copper and 800,000 ounces of gold. Guidance provided during Q2 earnings conference call.

10:05 EDT Boeing says long-term strategy, fundamentals related to 737 MAX 'unchanged' - Says continues to engage global regulators and customers on 737 MAX safe return to service. Says booked $4.9B after-tax charge and increased costs of $1.7B related to 737 MAX in Q2. Says delivered 90 commercial airplanes, including 42 787s, in Q2. Says commercial aviation remains long-term growth industry, with a 20-year commercial market outlook of 44,040 airplanes. Says long-term strategy, fundamentals related to the 737 MAX remain unchanged. Says focused on 737 MAX safe return to service. Comments from slides being presented on the Q2 earnings conference call.

10:02 EDT Air Products buys back two air separation units from Shanxi Jinmei Huayu - Air Products announced it has recently completed the buyback of two air separation units from Shanxi Jinmei Huayu Coal Chemical Co., a subsidiary of China's coal mining conglomerate Shanxi Jincheng Anthracite Coal Mining Group. Air Products has also started supplying since the end of June oxygen, nitrogen and other industrial gases via pipeline under a long-term supply agreement to Jinmei Huayu's major coal-to-clean fuels project in Jincheng City, Shanxi Province, China."Air Products supplied two ASUs-with a total capacity of over 4,000 tons per day-for Jinmei Huayu's Phase One energy project in Jincheng, which uses coal to produce one million tons of clean fuels annually. The two companies then actively explored further cooperation opportunities and later signed an agreement for Air Products to buy back the two ASUs for approximately $100M and provide Jinmei Huayu with long-term, safe and reliable industrial gas supply," the company stated.

10:00 EDT RPC, Inc. falls -10.3% - RPC, Inc. is down -10.3%, or -68c to $5.91.

10:00 EDT Tupperware Brands falls -13.7% - Tupperware Brands is down -13.7%, or -$2.44 to $15.38.

10:00 EDT M/I Homes rises 12.7% - M/I Homes is up 12.7%, or $3.67 to $32.59.

09:55 EDT Mettler-Toledo slides as short-seller Spruce Point sees up to 50% downside - Shares of Mettler-Toledo (MTD) are under pressure on Wednesday after Spruce Point named it a short idea, saying it found "strong evidence of aggressive financial, tax and capitalization and inventory accounting policies used to bolster earnings." Further, Spruce Point noted that its diligence into the company's China business showed "evidence of significant revenue, cash, and asset discrepancies," and that it sees 30%-50% downside once "investors' dissect Mettler's EPS quality and realize its valuation is extreme." STRONG SELL: In a newly published report, Spruce Point initiated Mettler-Toledo, formerly known as Taser International, with a Strong Sell as it has "significant concerns" about the company. "Since CEO Olivier Filliol took over in 2008, Mettler's ability to never miss quarterly Wall St earnings estimates raises doubts about the quality of its financial statements. Run by a secretive management team in Switzerland, and with key U.S.-based financial, tax, and audit managers all having worked at current auditor PwC, we worry that adequate, independent questioning of its financial results are lacking. [...] We find strong evidence of aggressive financial, tax and capitalization and inventory accounting policies used to bolster earnings. Outlandish share repurchases are being conducted at 36x P/E, which rewards management with cash bonuses for buying stock. [...] Our diligence into Mettler's China business shows evidence of significant revenue, cash, and asset discrepancies. We believe this suggests potential profit overstatement, especially in light of our findings that Mettler runs significant financial activity through shell entities with tax addresses that could not be located by investigators. We call for an independent committee to evaluate our findings. With the average Wall St. analyst price target at $705 per share, there's an implied 14% downside just on valuation along. We see 30%-50% downside once investors' dissect Mettler's EPS quality and realize its valuation is extreme," the report reads. PRICE ACTION: In morning trading, shares of Metter-Toledo have dropped over 3% to $792.67. Reference Link

09:47 EDT Marine Products rises 9.4% - Marine Products is up 9.4%, or $1.25 to $14.48.

09:47 EDT Edwards Lifesciences rises 11.7% - Edwards Lifesciences is up 11.7%, or $22.85 to $218.31.

09:41 EDT Mettler-Toledo falls after Spruce Point predicts up to 50% share downside - Shares of Mettler-Toledo are falling after Spruce Point Capital Management, best known for its short calls, issued a new report on the company. The firm sees 30%-50% downside risk in the stock. Shares of Mettler-Toledo are down 5%, or $39.74, to $777.67 in early trading. Spruce Point said it has "significant concerns" about the company. "Since CEO Olivier Filliol took over in 2008, Mettler's ability to never miss quarterly Wall St earnings estimates raises doubts about the quality of its financial statements. Run by secretive management in Switzerland, and with key U.S.-based financial, tax, and audit managers all having worked at current auditor PwC, we worry that adequate, independent questioning of its financial results are lacking," the firm said in its report. Reference Link

09:36 EDT LGC Capital says EU GMP facility for Evolution BNK moves towards approval - LGC Capital announced that Evolution BNK's Italian certifying consultants Studio Sannino S.a.s have advised that Evolution BNK has now received its ISO 9001:2015 Certification for Production, processing, marketing of products derived from Industrial hemp for its Pavia facility in Italy. The following certification processes are now proceeding and under review from the relevant authorities: Agricultural sector certifications: Management system for Good Agricultural and Collection Practice and Good Manufacturing Practice: industrial hemp cultivation; Good agronomic cultivation practices. Patent poisons - phytosanitary. Certification of the indoor production sector and production trade: Good Manufacturing Practice: Production, processing, marketing of products derived from industrial hemp. Compliance with GMP requirements implies health and processing requirements for internationally coded good practices, applicable to all processing plants. The GMP certification scheme for product processing will be based on the HACCP system, ISO 22000, ISO 9001. The implemented scheme will be certified for the analysis of good production standards and will provide an independent verification of compliance with the production rules and the prerequisites necessary for the implementation of an effective production safety program based on the HACCP scheme. Certification of the cosmetic production sector and marketing of cosmetic products: Implementation of GMP Management System based on ISO 22716. The aim is the guarantee of product safety and health of final consumers.

09:33 EDT Mettler-Toledo down 4% after named a short idea by Spruce Point - In early trading, Mettler-Toledo shares are down 4% to $785.27.

09:29 EDT Q.E.P. Company CEO Lewis Gold purchases shares valued at $275,000 - Q.E.P. CO. announced today that its Chairman and CEO Lewis Gould, has purchased shares of QEP common stock on the open-market having an aggregate value of approximately $275,000. This purchase adds to Mr. Gould's controlling interest in the company.

09:27 EDT Social Reality partners with LiveXLive Mto offer first music rewards on BIGtoken - Social Reality (SRAX) and LiveXLive Media (LIVX) have entered into a strategic partnership designed to increase each platform's user base while generating data-based insight. SRAX's BIGtoken, a platform for people to own and earn from their personal data, will enable its 16 million users to exchange their points, which are earned by sharing data, for LiveXLive premium subscriptions. BIGtoken will also reward points for users who refer family and friends to LiveXLive. LiveXLive will drive users to BIGtoken by introducing its 30 million addressable users to BIGtoken opportunities.

09:25 EDT Armour Residential appoints Z. Jamie Behar to board increasing size to nine - ARMOUR Residential REIT announced that the Board of Directors of the Company has appointed Z. Jamie Behar as an independent member of the Board, effective immediately. Behar has also been appointed as a member of the Audit Committee, effective immediately. The addition of Behar to the Board increases the size of the Board from nine members to ten members, six members of whom are now independent under the corporate governance listing standards of the New York Stock Exchange. Behar was Managing Director, Real Estate & Alternative Investments, for GM Investment Management Corporation.

09:22 EDT AT&T CEO: Going to be 'a little guarded' about digital subscriber count for HBO - AT&T CEO Randall Stephenson said management is going to be "a little guarded" about HBO digital subscribers until "we get a good handle on this." Stephenson added that management will give more information at the Warner Media Day, in October.

09:17 EDT Pressure BioSciences announces contract services agreement utilizing BaroFold - Pressure BioSciences announced it has signed a contract services agreement with a multi-billion dollar biotherapeutics company to enhance the process manufacturing of one of their candidate protein drugs. r. Alexander Lazarev, Chief Science Officer of PBI, said: "The BaroFold platform can be applied to the development and production of many different therapeutic proteins, can improve product safety, and is scalable and practical for standard bioprocess environments. Moreover, it offers ways to reduce or eliminate the use of aggressive chemicals in the protein manufacturing process. Thus, we believe this unique technology platform can help biopharmaceutical companies create and manufacture high quality novel protein therapeutics and biosimilars, lower the cost of existing formulations, and help protect our environment."

09:15 EDT AT&T CEO says HBO Max will have 'live elements', like sports, news

09:15 EDT ShotSpotter announces trauma collaboration with Stanford University - ShotSpotter announced a collaboration with the Stanford University School of Medicine to conduct a California-based, multi-center retrospective clinical study. The goal of the study is to determine the impact ShotSpotter technology has had on transportation time to a hospital, the number of field interventions, and gunshot victim patient outcomes. Decreasing response time to a gunshot incident by minutes provides those on the front line with a greater ability to save lives. ShotSpotter will provide gunshot data from 2014 - 2018 for select California ShotSpotter cities, with the initial phase covering East Palo Alto. The second phase will expand to cover additional Northern California cities - including Oakland, Fresno and Richmond - who have been longtime users of ShotSpotter's gunshot detection technology. Data from more than 5,000 gunshot wound victims will be analyzed including law enforcement, EMS, ShotSpotter and trauma registries.

09:13 EDT AT&T says if Sprint/T-Mobile happens or not, doesn't change strategy - AT&T (T) CEO Randall Stephenson said whether the Sprint (S) and T-Mobile (TMUS) merger happens or not, it doesn't change what AT&T is doing "over the next 3 years."

09:11 EDT GeoVax Labs presents data from HIV Vaccine study - GeoVax Labs announced that Harriet Robinson, PhD, CSO Emeritus and Director of the Company's HIV Vaccine program, delivered an oral presentation entitled, Protein-Supplemented DNA/MVA Vaccines: Preclinical Immunogenicity and Protection for Transmitted/Founder and CD4-induced gp120 Proteins, during the 10th International AIDS Society Conference. In her talk, Dr. Robinson reported on studies in 72 rhesus macaques evaluating the effects of the addition of gp120 proteins to the MVA boosts of a DNA prime-MVA boost vaccine regimen. The gp120 boosts consisted of a gp120 protein from a transmitted/founder virus and a CD4 receptor-induced gp120 protein. Both intramuscular and subcutaneous delivery of the boosts were tested. The gp120 boosts strongly enhanced the magnitude and breadth of binding antibodies to gp120. The CD4-induced, but not the transmitted/founder gp120, strongly enhanced bAbs for the V1V2 region of gp120, a specificity that correlated with reduced infection in the partially successful RV144 HIV vaccine trial in Thailand. The subcutaneous, but not the intramuscular injections, for the gp120 proteins reduced the level of post challenge infection. A similar study in humans is advancing in clinical trials through the HIV Vaccine Trials Network.The HVTN is supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health. "In response to these studies in non-human primates, our next clinical trial in humans will compare subcutaneous with intramuscular deliveries of protein boosts and whether the simpler monovalent CD4-induced gp120 is as effective at eliciting the desired antibody responses as the bivalent protein boost," said Dr. Robinson. "The first inoculations in HVTN 132 are anticipated to take place during the second half of 2019."

09:10 EDT AT&T looking to sell wireless towers in U.S., Mexico - Management said there are still a lot of opportunities to sell assets.

09:07 EDT Imax and Cineworld agree to expand Laser systems to 15 new theaters - IMAX and Cineworld Group announced an agreement to bring 15 new IMAX with Laser systems to Regal theatres across the U.S. The new agreement expands Cineworld and IMAX's partnership and builds on an agreement for 55 new IMAX with Laser systems signed by the companies in April 2018. Overall, Cineworld has more than 170 IMAX theatres currently in operation or contracted to open throughout the U.S. and Europe. The upgraded theatres will include IMAX's laser technology and 12-channel sound system, as well as enhancements including luxury plush rocker seating, redesigned entryways and in-theatre branding.

08:59 EDT Thermo Fisher says expects foreign exchange to have a negative impact in FY19 - Says had data center outage a few days ago. Says financial impact from data center outage is not material to FY19. Says feels good about markets. Says continues to increase bioprocessing capabilities. Says data center outage delayed some shipments. Says ended Q2 with $2.3B in cash and investments. Sees $30M tariff impact. Comments taken from Q2 earnings conference call.

08:55 EDT AIG appoints Jennifer Waldner as Chief Sustainability Officer - American International Group announced that it has created a position of Chief Sustainability Officer to lead the development and implementation of a company-wide sustainability strategy and appointed Jennifer Waldner to fill the role, effective immediately. Waldner will report to Thomas Leonardi, AIG's Executive Vice President and Vice Chair, AIG Life Holdings. Waldner has accountability for implementing AIG's sustainability strategy and developing a corresponding reporting structure. For the past ten years, she has held positions of increasing responsibility within AIG focused on these areas, most recently as Head of Citizenship for AIG Life and Retirement.

08:51 EDT Reebonz Holding expands 'Sell to Reebonz' service to jewelry - Reebonz Holding announced that it has expanded its "Sell to Reebonz" service to selected jewelry and accessories. With this category expansion, Reebonz aims to deepen its relationship with customers and provide more options on products that can be sold back to the platform. Reebonz originally launched the "Sell to Reebonz" service in May 2019 in Singapore in categories such as Bags, Small Leather Goods and Watches. With a pre-populated list of products, customers can expedite the selling process by choosing the product they want to sell, and quickly receive Reebonz Credits for the products that are successfully accepted. With Reebonz Credits in their account, customers can make additional purchases and offset some of the costs. Reebonz recently expanded the "Sell to Reebonz" service in Malaysia, Indonesia, Hong Kong, Taiwan, and Australia.

08:49 EDT BioTelemetry acquires ADEA Medical AB, terms not disclosed - BioTelemetry announced that it has acquired ADEA Medical AB, an early-stage Swedish medical technology company that delivers remote health services in the Nordics. The acquisition is aligned with BioTelemetry's longer-term strategy to increase its international footprint and offer its products and services to physicians and patients in the Nordics and other parts of Europe.

08:43 EDT Massachusetts authorizes Verizon to provide services on public safety contract - The Commonwealth of Massachusetts has authorized Verizon to offer services to public safety through the state's public safety grade wireless agreement. Verizon services include Responder Private Core, priority and preemption technology for first responders in the Commonwealth. This is the first state and local agency multi-vendor procurement in the nation for public safety grade wireless data services. Verizon's public safety grade wireless data services are designed to enhance first responders' abilities to protect human life and property. The data services provided by Verizon feature: Virtualized separate 4G LTE core, maximizing security for public safety users. 3rd Generation Partnership Project standards to implement Quality of Service, priority, and preemption for public safety data communications.

08:40 EDT UPS says made 'significant progress' executing strategies in Q2 - Says: This is an exciting time at UPS... Adding highly efficient aircraft in U.S... Market share growth is accelerating... Opened three new sorting hubs in Q2, adding 2M square feet... Needs to see more progress on U.S./China trade relations... Prolonged uncertainty on global trade. Comments taken from Q2 earnings conference call.

08:38 EDT GM Cruise says company, Honda developing self-driving car

08:36 EDT DelMar Pharmaceuticals enrolls first patient in Phase 2 study of VAL-083 - DelMar Pharmaceuticals announced that the first patient has been treated in the adjuvant - pre-temozolomide maintenance - trial arm of VAL-083's Phase 2 study in MGMT-unmethylated glioblastoma multiforme, or GBM, being conducted at the University of Texas MD Anderson Cancer Center. This recently-approved arm of the study will enroll up to 24 newly-diagnosed patients who have undergone surgery and chemoradiation with temozolomide - TMZ - but will now receive VAL-083 in place of standard of care TMZ for adjuvant therapy. This adjuvant arm, which was recently approved by the MDACC Institutional Review Board, will provide early disease data on VAL-083, in contrast to those patients enrolling in the company's original recurrent trial arm of the MDACC clinical study who have typically been heavily pre-treated with TMZ prior to disease recurrence. InDelMar is actively enrolling patients for both trial arms of the clinical study at MDACC. Concurrently, the company is conducting a Phase 2 clinical study of VAL-083 as first line treatment for GBM in combination with radiotherapy in China. VAL-083 has been granted orphan drug designations by the U.S. FDA Office of Orphan Products for the treatment of glioma, medulloblastoma and ovarian cancer, and in Europe for the treatment of malignant gliomas. It has also been granted fast-track status for the treatment of recurrent GBM by the FDA.

08:33 EDT Meet Group enters partnership with Yoti - Meet Group and Yoti, a digital identity company, announced that The Meet Group plans to trial Yoti's innovative age verification and age estimation technologies designed to create safer communities online. The relationship allows Yoti to enhance The Meet Group's strong existing safety measures, letting users verify their age with Yoti's age estimation technology Yoti Age Scan, or the free Yoti app where a date of birth is verified to a government issued photo ID. Yoti's technology can help moderators at The Meet Group ensure that minors do not create accounts.

08:33 EDT OSI Systems receives $10M in orders for patient monitoring solutions - OSI Systems announced that its Healthcare division, Spacelabs Healthcare, received orders valued at approximately $10M to provide patient monitoring solutions and related accessories to a U.S. hospital. Spacelabs will provide central stations, high-acuity bedside and transport monitors, as well as ambulatory patient monitors and related telemetry solutions.

08:31 EDT Aytu BioScience says Natesto added to national PBM's formulary - Aytu BioScience announced that Natesto is now on formulary and covered nationwide by a leading national pharmacy benefit manager. This PBM contract provides for unrestricted patient access to Natesto across the PBM's national open formularies and plans that service government clients. Over six million U.S. lives are covered by these prescription plans. Josh Disbrow, CEO of Aytu BioScience stated, "The addition of Natesto to a large national formulary is an important step in further building this important brand in the United States. With the signing of this payer contract, over six million new patients have gained access to Natesto. We expect this expanded coverage to increase physician prescribing of Natesto and to enable improved access to the more than 13 million U.S. men diagnosed with hypogonadism."

08:29 EDT Crop's first California extracts pass pesticide, heavy metal testing - CROP INFRASTRUCTURE CORP announced that its first batch of THC distillate cartridges derived from the 2018 harvest have passed heavy metal and pesticide testing consistent with the excellent initial test results after the 2018 harvest. The packaging team has now resumed filling cartridges in preparation of the launch of Evolution Cannabis and Hempire brands in California. Furthermore, the first two greenhouses at the Humboldt organic farm have been harvested and are awaiting trimming, testing and packaging. This will allow the company to launch its premium distillate line and organic fresh flower SKUs into the California market through internal sales and the partially owned Flip Distro, giving sales teams a full suite of products to offer retailers.

08:26 EDT Rhythm Pharmaceuticals appoints Stuart Arbuckle to board of directors - Rhythm Pharmaceuticals (RYTM) announced the appointment of Stuart Arbuckle to its Board of Directors. Arbuckle currently serves as EVP and CCO at Vertex Pharmaceuticals (VRTX).

08:23 EDT Melco Resorts & Entertainment increase quarterly dividend 6% to 5.5c per share - The company said, ""The Board has, after evaluating the Company's current liquidity position and future expected capital needs, decided to increase the quarterly cash dividend by 6% to 5.504c per ordinary share, which is equivalent to 16.512c per ADS, from the previous quarterly dividend of 5.17c per ordinary share."

08:15 EDT Mnuchin says 'no question' that Amazon limits competition - Treasury Secretary Steve Mnuchin said while being interviewed on CNBC that there is "no question" that Amazon limits competition and that it has "destroyed" the retail industry in the U.S. The DOJ review of technology companies is good for the U.S., Mnuchin added.

08:11 EDT OncoCyte appoints Melinda Griffith to board of directors - OncoCyte Corporation announced the appointment of Melinda Griffith to its Board of Directors. In addition to her board appointment for OncoCyte, she currently serves as VP of Strategic Alliances and chief legal counsel for the Parker Institute for Cancer Immunotherapy.

08:10 EDT Mnuchin doesn't see areas where Google working with China raises concerns - Treasury Secretary Steve Mnuchin said while being interviewed on CNBC that he does not see any area in which Google is working with the Chinese government that raises concerns in any way.

08:08 EDT NeuBase Therapeutics appoints Danith Ly as CSO - NeuBase Therapeutics announced the appointment of Danith Ly, Ph.D., as chief scientific officer. Ly is the primary inventor of NeuBase's peptide nucleic acid antisense oligonucleotide platform technology, which the Company is leveraging to develop a pipeline of gene modifying therapies. Ly joins NeuBase as the Company is advancing its first PATrOL-enabled therapies through preclinical development and expanding its pipeline across rare genetic diseases as well as additional genetically-driven disorders. In addition to his role at NeuBase, Ly will maintain his faculty appointment at Carnegie Mellon University's Mellon College of Science.

08:07 EDT Ekso Bionics expands medical portfolio with EksoUE upper body exoskeleton - Ekso Bionics Holdings announced the expansion of its medical exoskeleton portfolio with an upper extremity rehabilitation device called EksoUE. The wearable upper body exoskeleton assists patients with a broad range of upper extremity impairment and aims to provide them with a wider range of motion and increased endurance for rehabilitation sessions of higher dose and intensity. Through a collaboration between Ekso Bionics and The Johns Hopkins University School of Medicine, the concept of EksoUE was beta-tested by the KATA Design Studio. Together, Ekso Bionics and the KATA team explored the potential for an upper body exoskeleton to assist with different functions and tasks during rehabilitation in a traditional clinical setting, as well as combined with new interactive technologies. During the development stage, Burke Neurological Institute, provided patient and clinician feedback on the device. EksoUE was tested primarily with stroke patients yet has applications for various upper extremity impairments. The wearable upper body exoskeleton is put on similar to a jacket, secured at the waist, and on the arms and wrists. Lift assistance is provided by passive mechanisms located on the arms and does not require any battery power. EksoUE is registered with the FDA as a class I medical device. EksoUE will first be made available to select existing customers through a limited release, with plans to make it commercially available in the U.S. and Europe by end of year.

08:06 EDT 111, Inc. signs strategic cooperation agreement with Harbin Pharmaceutical Group - 111, Inc. announced the signing of a strategic cooperation agreement with Harbin Pharmaceutical Group Holding Co., which has selected 111 as its primary partner for online sales of Over the Counter products. The agreement will enable both companies to serve customers by providing access to high-quality products and services.

08:05 EDT EchoStar subsidiary Hughes awarded $11.8M U.S. Army contract - Hughes Network Systems announced it has been awarded an $11.8M R&D contract by the U.S. Army, answering its requirement for improved resiliency and interoperability among SATCOM systems for military communications. The contract calls for Hughes to demonstrate a new, end-to-end Narrowband SATCOM Architecture incorporating Machine Learning and Artificial Intelligence features designed to improve three critical areas - network management, automated control, and system interoperability - for the U.S. Army Combat Capabilities Development Command, C5ISR Center, Space and Terrestrial Communications Directorate.

08:03 EDT Remark Holdings says interim CFO Alison Davidson to step down on August 2 - Remark Holdings announced that Alison Davidson, the company's Interim CFO, will step down on August 2. Davidson will be relocating to the East Coast with her family and will therefore pursue other endeavors. The company also announced that it is in the final stages of the CFO search process and expects to name a new CFO soon.

08:01 EDT Norfolk Southern reports Q2 operating ratio 63.6%

07:46 EDT Quaker Chemical and Houghton International merger receives final approval - Quaker Chemical and Houghton International received approval from the U.S. Federal Trade Commission for their combination. This was the final approval required. The approval is subject to the divestiture of certain product lines comprising approximately 3% of combined company revenue which is consistent with previous guidance. The divestiture will occur concurrent with the close of the combination which is expected to be on August 1.

07:44 EDT Cytokinetics announces publication of preclinical data on FTSA - Cytokinetics, Incorporated announced the publication of data in The Journal of Physiology demonstrating that a fast skeletal muscle troponin activator can decrease skeletal muscle fatigue by increasing the metabolic efficiency of muscle contraction. The manuscript, titled "Fast Skeletal Muscle Troponin Activator CK-2066260 Increases Fatigue Resistance by Reducing the Energetic Cost of Muscle Contraction," was published this month. Cytokinetics conducted the research in collaboration with the laboratory of Professor Hakan Westerblad at the Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. CK-2066260 is a preclinical tool compound of the FSTA class. CK-2066260 is a FSTA from the same chemical structural series as tirasemtiv, the first-generation FSTA discovered and developed by Cytokinetics. Similar to tirasemtiv and reldesemtiv, the next-generation FSTA from a distinct chemical series, being developed in collaboration with Astellas for the potential treatment of neuromuscular diseases of impaired muscle function, CK-2066260 binds directly to fast skeletal muscle troponin, increases myofibrillar calcium sensitivity and amplifies the force response to submaximal nerve stimulation. The regulation of calcium levels associated with muscle excitation and contraction account for a significant amount of muscle energy utilization. Because a FSTA lowers the amount of calcium required to produce a given muscle force, the authors hypothesized that CK-2066260 could reduce the energetic cost of muscle activation, allowing muscle to contract for longer. Key results from a series of in vitro, in situ and in vivo rodent experiments demonstrated that treatment with CK-2066260: Amplified the muscle force response to subtetanic electrical stimulation by increasing muscle calcium sensitivity; Improved the force response under fatiguing conditions; Produced muscle force at lower cytosolic calcium concentrations and accompanied by reduced ATP demand and muscle glycogen usage; Improved exercise capacity in healthy rats and a rat model of peripheral artery insufficiency.

07:42 EDT Primoris announces engineering award for renewable natural gas facility - Primoris Services Corporation announced a new engineering award, secured by OnQuest, part of the Power, Industrial, & Engineering segment. The award is for engineering, procurement, and construction management services for a renewable natural gas facility in the Midwestern United States. The project will recover biogas from multiple farm sites and pipe it to a central processing facility. Work is scheduled to commence in the third quarter of 2019, and completion is expected in the third quarter of 2020.

07:41 EDT Boeing: Cash and marketable securities of $9.6B provide strong liquidity

07:36 EDT Caterpillar sees rest of FY19 restructuring costs to be lower - The company states: "The company continues to expect modest sales growth in 2019, which assumes a recovery in Oil and Gas near the end of the year and dealers working through higher machine inventory levels. The company still expects price realization to offset manufacturing costs. With a higher amount of restructuring costs incurred in the second quarter of 2019, the company expects restructuring costs for the remainder of the year to be significantly lower."

07:34 EDT Caterpillar Q2 dealer machine/engine inventories rose $500M vs. $100M last year - Q2 order backlog was $15.0B, down by about $1.9B from Q1.

07:33 EDT Boeing: Previously issued 2019 guidance does not reflect 737 MAX impacts - "The previously issued 2019 financial guidance does not reflect 737 MAX impacts. Due to the uncertainty of the timing and conditions surrounding return to service of the 737 MAX fleet, new guidance will be issued at a future date. Boeing is working very closely with the FAA on the process they have laid out to certify the 737 MAX software update and safely return the MAX to service. Disciplined development and testing is underway and we will submit the final software package to the FAA once we have satisfied all of their certification requirements. Regulatory authorities will determine the process for certifying the MAX software and training updates as well as the timing for lifting the grounding order." "This is a defining moment for Boeing and we remain focused on our enduring values of safety, quality, and integrity in all that we do, as we work to safely return the 737 MAX to service," said Boeing Chairman, President and CEO Dennis Muilenburg. "During these challenging times, teams across our enterprise continue to perform at a high level while delivering on commitments and capturing new opportunities driven by strong, long-term fundamentals."

07:31 EDT Boeing: Previously issued 2019 guidance does not reflect 737 MAX impacts - New guidance to be issued at a future date.

07:28 EDT CURE Pharmaceutical receives patent on high loading in oral thin films - CURE Pharmaceutical announced the allowance of U.S. Application No. 13/890,875. The new patent builds on one of CURE's key technology differentiators - loading higher amounts of drug active on an oral thin film using its proprietary drug delivery system, CUREfilm. The new patent covers methods of preparing edible thin films that can deliver high doses of active ingredients that are encapsulated using lipids to form micelles or liposomes. This enables CURE to differentiate its OTF product for specific drug opportunities such as cannabidiol and sildenafil oral soluble films.

07:20 EDT CX Industries signs exclusive licensing agreement with Ignite International - WeedMD, its wholly-owned subsidiary CX Industries and Ignite International Brands announced they have entered into an exclusive licensing agreement for an initial term of two years with an option for a third year. The initial product launch will include a variety of THC and CBD products for the Canadian market. CX, which specializes in extraction, tolling, licensing and innovative third-party product formulations from WeedMD's fully-licensed Aylmer, Ontario facility, will be the extractor, packager and distributor of Ignite-branded vape products and cartridges in Canada. CX Industries is expected to have the capacity to process over 200,000 kilograms of biomass in 2020 and expects to begin processing roughly 20,000 kilograms of biomass delivered from WeedMD's first harvest in Q4 2019.

07:16 EDT Trillium Therapeutics schedules meeting with FDA to discuss path for TTI-621 - Trillium Therapeutics provided a corporate update. "Trillium continues to make progress with both our intratumoral and intravenous development programs for TTI-621, our novel CD47 immune checkpoint inhibitor," said Robert L. Kirkman, M.D., Executive Chair of Trillium. "We believe the single agent anti-tumor activity we have observed in our trials of TTI-621 to date is unique and, as we move these programs forward, positions Trillium to be a leader in this exciting new approach to the treatment of cancer." Trillium is focusing the intratumoral administration of TTI-621 for the treatment of cutaneous T-cell lymphoma. The U.S. Food and Drug Administration has accepted the Company's request for an in-person meeting, currently scheduled to take place later this quarter, to discuss the Company's proposed pivotal pathway for intratumoral administration of TTI-621 in early-stage CTCL. This proposal builds upon the anti-tumor activity observed in the ongoing phase 1b expansion trial. As reported at the American Society of Hematology meeting in December 2018, a reduction in Composite Assessment of Index Lesion Severity scores, which measure local lesion responses, was observed in 91% of CTCL patients receiving intratumoral TTI-621. The current goal of Trillium's intravenous program for TTI-621 is the identification of a recommended phase 2 dose. Trillium has amended the intravenous study protocol to enable dosing beyond 0.5 mg/kg and is currently enrolling the first cohort in the new dose-escalation design. The Company also has completed enrollment for the first Simon's 2-stage CTCL cohort in the TTI-621 intravenous study. The Safety Review Committee reviewed the preliminary data from this cohort and recommended that patients on study continue to be followed until all response assessments are available. The Company has decided not to initiate the second Simon's 2-stage cohort until the outcome of the ongoing dose escalation is known. "While we have seen meaningful activity of intravenous TTI-621 in a variety of malignancies at the current doses, we believe it is important to identify the optimal dose before proceeding with additional studies," said CMO Yaping Shou. "We believe this approach is the best use of resources and will maximize the opportunity for success."

07:11 EDT Dunkin' Brands and Beyond Meat launching plant-based sandwich in NY - Dunkin' Brands (DNKN) announced a new partnership with Beyond Meat (BYND) to introduce the Beyond Sausage Breakfast Sandwich, available now at participating Dunkin' restaurants in Manhattan with plans for a future national rollout. Dunkin' is holding a special Beyond Sausage Breakfast Sandwich tasting event.

07:06 EDT UPS sees FY19 adjusted free cash flow $3.5B-$4B - "UPS grew profits across all business segments," said Richard Peretz, UPS's CFO. "Our performance was driven by the efficiencies created by investments in our network, the success of ongoing initiatives and our ability to execute in an ever-changing environment. We expect to carry this momentum through the upcoming quarters." The company's full-year adjusted diluted EPS will be in the range of $7.45 to $7.75. Adjusted free cash flow for the year is projected to be between $3.5 and $4 billion with potential additional upside from the working capital initiatives. The effective tax rate for the full-year 2019 is estimated to be between 22% and 24%. Third-quarter adjusted EPS is expected to benefit from numerous items including one additional operating day and year-over-year International benefits from 2018 commodities headwinds that should not repeat. Transformation charges and pension MTM are not included in the adjusted guidance.

07:05 EDT ParkerVision: Court paves way for infringement case to proceed against Qualcomm - ParkerVision (PRKR) announced that the District Court for the Middle District of Florida granted ParkerVision's proposed selection of patent claims from four asserted patents and denied Qualcomm's (QCOM) request to limit the claims and patents, including claims that survived Qualcomm's validity challenges through Inter Partes Review. The court also agreed that ParkerVision may elect to pursue accused products that were at issue at the time the case was stayed, as well as new products that were released by Qualcomm during the pendency of the stay. This decision from the court comes following an oral hearing held May 22, 2019. Jeffrey Parker, CEO of ParkerVision stated, "We are pleased that the District Court did not allow Qualcomm to limit our ability to assert patent claims in this case, particularly those claims that Qualcomm unsuccessfully challenged through IPRs and a subsequent appeal to the Federal Circuit. Defendants often initiate IPR proceedings in an attempt to invalidate the patents they are accused of infringing. The court recognized in its order, that ParkerVision's request to elect certain claims comes after a three-year delay in the proceedings caused by Qualcomm's initiation of IPR proceedings, and that ParkerVision acted promptly once the appellate review was complete."

07:01 EDT Speedway Motorsports, Sonic Financial enter definitive merger agreement - Speedway Motorsports and Sonic Financial announced that they, along with a wholly owned acquisition subsidiary of Sonic Financial, have entered into a definitive merger agreement for Sonic Financial's subsidiary to acquire all of the outstanding shares of common stock of the Company for cash consideration of $19.75 per share. The per share price represents a premium of approximately 42% to the closing price of the company's common stock on April 23, the day before Sonic Financial's nonbinding proposal was first announced. Sonic Financial, O. Bruton Smith, his family and related entities beneficially own, directly or indirectly, approximately 29M shares of the company, and control over 71% of the voting power of the company. The merger agreement was unanimously approved by the company's board of directors upon the unanimous recommendation of a special committee comprised solely of independent and disinterested members of the company's board of directors. Under the terms of the merger agreement, Sonic Financial's subsidiary will promptly commence a tender offer to acquire all of the outstanding shares of the company's common stock at a price of $19.75 per share in cash. The closing of the tender offer will be subject to several conditions, including the tender by more than 50% of the outstanding shares of common stock of the company not held by the Smith Group and certain other related parties and other customary conditions. After completion of the tender offer, Sonic Financial will acquire all remaining shares of company stock not held by Sonic Financial or its subsidiary at the same price of $19.75 per share through a statutory merger of Sonic Financial's subsidiary and the company in which the company will be the surviving corporation and will become a wholly owned subsidiary of Sonic Financial. Under Delaware law, stockholders are not required to approve this statutory merger. The closing of the tender offer and merger transaction is expected to take place in the third quarter.

06:58 EDT Speedway Motorsports, Sonic Financial enter definitive merger agreement

06:53 EDT Central Pacific invests $40M on RISE2020 initiative - RISE2020 includes initiatives in the following areas of opportunity: digital banking, revenue enhancements, branch transformation and operational excellence. RISE2020 will provide Central Pacific Bank with products and services in several strategic areas. The company anticipates investing roughly $40M in RISE2020 and expects the initiative to lead to enhanced profitability that will result in a 15% return on average shareholders' equity and a 57% efficiency ratio by the end of 2022. Q2 included roughly $1M of RISE2020-related expense. The company will share more on RISE2020 on its conference call and in future quarters.

06:44 EDT Sage Therapeutics provides clinical update of neuroscience pipeline - Sage Therapeutics reported clinical progress in select depression, neurology, and neuropsychiatry franchise programs. Sage is advancing a portfolio of novel and differentiated product candidates designed to improve brain health by targeting the GABA and NMDA receptor systems. In its depression program, data from the Phase 2 open-label study of SAGE-217 in bipolar depression demonstrated rapid improvement compared to baseline; and analysis of datasets from previously completed studies revealed encouraging findings relevant to the development of SAGE-217 in treatment-resistant depression and generalized anxiety disorder. SAGE-217 was generally well-tolerated, the most common adverse events being somnolence, headache, diarrhea, and sedation. There were two cases of transient hypomania off-treatment; no mania or serious adverse events was reported in the trial. In neurology programs, data from Phase 1 study with SAGE-324 shows activity in essential tremor; differentiated profile opens potential pathways for development in additional neurological indications. Results demonstrate a pharmacokinetic profile suitable for chronic dosing in indications amenable to the GABA PAM mechanism. Sage plans to initiate a Phase 2 study evaluating SAGE-324 in essential tremor in 2H 2019. This study will also inform clinical expansion into adjacent opportunities in neurological conditions such as epileptiform disorders and Parkinson's. In its neuropsychiatry franchise, data from Phase 1 program for SAGE-718, Sage's lead molecule in its NMDA portfolio, shows it was well-tolerated and improved executive function compared to placebo in healthy volunteers, , and was generally safe and well-tolerated. Sage plans to move forward to evaluate SAGE-718 in Phase 2 development programs in neurodegenerative disorders and other conditions where executive function is impaired. Additional timing for these studies will be provided in 2H 2019.

06:36 EDT Arch Coal raises FY19 total sales volume to 86.7- 92.1 tons from 86.6-92 tons - "We remain highly confident in Arch's clearly defined strategy for long-term value creation and growth," CEO John Eaves said. "We are sharply focused on maximizing returns by executing on our strategy, and see multiple drivers for future value creation. These drivers include the continuation of our robust and proven capital return program; the development of our world-class, Leer South longwall mine; the transition of the Leer mine into the heart of its reserve base; and the completion of our recently announced joint venture with Peabody Energy. We believe these drivers - coupled with continued, strong operational execution - will position Arch to deliver long-term, sustainable returns for our shareholders."

06:34 EDT Northrop Grumman reports backlog increases 10% to $63B

06:32 EDT Daimler AG sees FY19 Group EBIT 'significantly below' prior-year level - Based on the measures taken, Daimler expects EBIT and free cash flow of the industrial business to improve significantly by the end of the fiscal year compared with the first half. Nevertheless, the anticipated development of earnings in the automotive business will partially have a negative impact. The ongoing high upfront expenditures for new products and technologies as well as the costs for Project Future to implement the new Group structure will be a burden. Under these conditions, Daimler expects the free cash flow of the industrial business in financial year 2019 to be significantly lower than in the previous year.

06:28 EDT AT&T CEO says 'on track to deliver on all our 2019 priorities' - "We're halfway through the year and on track to deliver on all our 2019 priorities," said Randall Stephenson, AT&T chairman and CEO. "We continue to pay down debt and are more confident than ever that we'll meet our yearend deleveraging goal, and we'll take a look at buying back stock. Our FirstNet build is not only running ahead of schedule - it's become a driver of our wireless network leadership in speed, reliability and network performance. It also sets us up to have nationwide commercially available 5G coverage in the first half of 2020. On top of all this, our operating teams continue to deliver solid results. Our wireless business grew revenues, profitability and phone customers, both postpaid and prepaid. WarnerMedia delivered another strong quarter with both revenue and operating income growth. And our Entertainment Group profitability continued to stabilize, and even grow. Across the board, it was a solid quarter that puts us in position to have a really strong year."

06:27 EDT Lexaria Bioscience reports manufacturing, licensing partnership with Hill Street - Lexaria Bioscience announced a multi-faceted expansion of their relationship with Hill Street Beverage Company. Hill Street and Lexaria have entered into a Joint Manufacturing Partnership valid for 10 years to produce jointly created DehydraTECHTM commercial products under a new brand to be announced, including processed THC cannabis and/or CBD hemp powder for new consumer products including among other categories; tablets, capsules, or packets for sale in Canada and for export where permitted. The JMP will also produce similar powders as a bulk ingredient for manufacturing processes for sale to other licensed producers seeking to use Lexaria's infusion technologies to create their own wide variety of products for sale within Canada. Manufacturing will be done at Hill Street's soon to be acquired OneLeaf Cannabis cultivation and processing facility in Regina, Saskatchewan, pending licensing by Health Canada. Hill Street will own and manage all aspects of the manufacturing business under Lexaria's own license and patents for DehydraTECH and its related processes. Profits from this business unit will be shared equally between Hill Street and Lexaria. In addition to the manufacturing partnership, Hill Street has acquired two global semi-exclusive licenses to utilize Lexaria's DehydraTECH THC beverage infusion technology, and to utilize Lexaria's DehydraTECH CBD beverage infusion technology around the world, valid for 10 years.

06:24 EDT Deutsche Bank: Negotiations on track for sale of Prime Finance - Deutsche Bank said: "Negotiations are on track for the sale of Prime Finance and the Electronic Equities platform to BNP Paribas. In Cash Equities, Deutsche Bank has exited positions and the shutdown of systems is in progress. Over 900 employees have either been given notice or informed that their role will be eliminated since the announcement of the transformation strategy."

06:23 EDT Vislink awarded order from NATO Communications and Information Agency - Vislink Technologies has signed a Basic Ordering Agreement with the NATO Communications and Information Agency. The scope of the agreement extends to the supply of Vislink MSAT and MANTIS satellite communication solutions and engineering services to NATO and NATO bodies, and includes any government agency, including military forces, of the twenty-nine NATO Member Nations. The BOA is a framework that enables a streamlined process for the eligible parties noted above to purchase satcom solutions directly from Vislink, as a pre-reviewed and prequalified NATO vendor, or by using NATO as their contracting agent.

06:14 EDT Nissan: Operating profit figure reported by Nikkei Shimbun 'broadly accurate' - On July 24, the Nikkei Shimbun published an article regarding Nissan's financial results for the first quarter of fiscal year 2019. The article was not based on any announcements by the company, Nissan said in a statement. "While the financial results for the quarter are still being reviewed, the operating profit figure reported in the Nikkei Shimbun article was broadly accurate. However, no official confirmation can be made until the final results have been approved by the company's board of directors tomorrow. Following that approval, the company plans to announce the results on the same day."

06:09 EDT Anthem sees FY19 medical membership 41M-41.3M - Prior view was 40.9M-41.3M. Benefit expense ratio is now expected to be in the range of 86.2% - 86.5%. SG&A ratio is now expected to be in the range of 13.2% - 13.5%. Cost of products sold is expected to be $1.6B- $1.8B. Operating cash flow is expected to be greater than $5.2B.

06:05 EDT Tenet completes strategic review, plans to complete spin-off by end of 2Q21 - Tenet Healthcare announced its intention to pursue a tax-free spin-off of its Conifer business as a separate, independent publicly traded company. The company expects to complete the spin-off by the end of the second quarter of 2021. This announcement is the culmination of the Conifer strategic review process announced in December 2017. Ronald A. Rittenmeyer, Executive Chairman and CEO, said, "After an extensive review of Conifer's strategic alternatives, in which we evaluated multiple options for the business while simultaneously driving significant and sustainable improvements in performance, we are pleased to announce plans to spin off Conifer into a separate, publicly traded company. This decision supports our longstanding objectives to maximize the value of Conifer, build on its strong growth potential and deliver the best outcome for Conifer and for Tenet shareholders." Rittenmeyer continued, "Conifer has unmatched experience and scale in offering revenue cycle management solutions for healthcare providers and a proven track record of delivering high-touch, high-value services to clients. Pursuing a tax-free spin-off is an important step forward in Conifer's evolution, and we believe the business is well-positioned to capitalize on its growth opportunities as a standalone company." Rittenmeyer added, "We were pleased with Tenet's performance in the second quarter, with Adjusted EBITDA comfortably within our Outlook range and consistent with consensus estimates. Volume growth strengthened in our hospital business, with increases in both admissions and adjusted admissions. USPI also delivered favorable volume growth and Conifer had another strong quarter. We remain excited about the future of our healthcare services offerings at our 65 hospitals and approximately 500 outpatient centers which will remain part of the Tenet enterprise." The separation process will include a thorough review of the necessary executive leadership changes, Board membership needs and key commercial milestones that Conifer must achieve in order to provide the optimal governance structures and business foundations for a successful public company. Specific details about these actions and milestones will be made available in due course. Among other things, the spin-off will be subject to finalization of the entity structure of the spun-off business, assurance that the separation will be tax-free to Tenet's shareholders for U.S. federal income tax purposes, executing a restructured services agreement between Conifer and Tenet, finalization of Conifer's capital structure, the effectiveness of appropriate filings with the Securities and Exchange Commission, final approval from the Tenet Board of Directors, and other customary conditions. The spin-off will not require a vote by Tenet shareholders and is supported by Common Spirit which owns a minority interest in Conifer Health Solutions, LLC. The transaction is being targeted for completion by the end of the second quarter of 2021, but there can be no assurance regarding the timeframe for completing the spin-off, the allocation of assets and liabilities between Tenet and Conifer, or that the spin-off will be completed at all.

06:00 EDT Anthem raises FY19 outlook

05:07 EDT Ballard Power announces order from Wrightbus for 15 fuel cell modules - Ballard Power announced a purchase order from Wrightbus for 15 FCveloCity-HD 85-kilowatt fuel cell modules to power buses for deployment in Aberdeen, Scotland under the Joint Initiative For Hydrogen Vehicles Across Europe, or JIVE, funding program. The 15 two deck, zero-emission StreetDeck fuel cell electric buses, or FCEBs, are 10.9 meters long and can carry up to 64 passengers. These buses share the same chassis with a battery electric version, but avoid the need for long battery recharging time, instead being refueled with hydrogen in less than 10 minutes. All the Ballard modules in this order are expected to ship by end-2019 and the buses are expected to be deployed with First Aberdeen transit agency by end-2020.